Disclosure of amyloid imaging results to research participants: Has the time come?

Alzheimer's and Dementia

Volumn 9, Issue 6, 2013, Pages 741-744.e2

  Lingler, Jennifer H ^a   Klunk, William E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alzheimer's disease; Amyloid; Biomarkers; Human subjects; Mild cognitive impairment; Neuroimaging; Positron emission tomography; Research ethics

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; PITTSBURGH COMPOUND B;

AGING; ALZHEIMER DISEASE; COGNITIVE DEFECT; HEALTH CARE PLANNING; HEALTH INSURANCE; HISTOPATHOLOGY; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PEER REVIEW; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRIVACY; QUALITY OF LIFE; REVIEW; SPORADIC CREUTZFELDT JAKOB DISEASE;

ALZHEIMER'S DISEASE; AMYLOID; BIOMARKERS; HUMAN SUBJECTS; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; RESEARCH ETHICS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOMEDICAL RESEARCH; DISCLOSURE; HUMANS; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; THIAZOLES;

EID: 84887479625     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.09.014     Document Type: Article

References (71)

1. W.E. Klunk Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia Neurobiol Aging 32 Suppl 1 2011 S20 S36
2. C.A. Mathis, Y. Wang, D.P. Holt, G.F. Huang, M.L. Debnath, and W.E. Klunk Synthesis and evaluation of 11C labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents J Med Chem 46 2003 2740 2754
3. W.E. Klunk, B.J. Lopresti, M.D. Ikonomovic, I.M. Lefterov, R.P. Koldamova, and E.E. Abrahamson Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid beta in Alzheimer's disease brain but not in transgenic mouse brain J Neurosci 25 2005 10598 10606
4. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, and D.P. Holt Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 2004 306 319
5. M.D. Ikonomovic, W.E. Klunk, E.E. Abrahamson, C.A. Mathis, J.C. Price, and N.D. Tsopelas Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain 131 2008 1630 1645
6. H. Braak, and E. Braak Frequency of stages of Alzheimer-related lesions in different age categories Neurobiol Aging 18 1997 351 357
7. D.R. Thal, U. Rub, M. Orantes, and H. Braak Phases of Aβ-deposition in the human brain and its relevance for the development of AD Neurology 58 2002 1791 1800
8. B.J. Bacskai, M.P. Frosch, S.H. Freeman, S.B. Raymond, J.C. Augustinack, and K.A. Johnson Molecular imaging with Pittsburgh Compound B confirmed at autopsy: A case report Arch Neurol 64 2007 431 434
9. N.J. Cairns, M.D. Ikonomovic, T. Benzinger, M. Storandt, A.M. Fagan, and A. Shah Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease Arch Neurol 66 2009 1557 1562
10. V.L. Villemagne, C.A. McLean, K. Reardon, A. Boyd, V. Lewis, and G. Klug 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease J Neurol Neurosurg Psychiatry 80 2009 998 1001
11. J. Sojkova, I. Driscoll, D. Iacono, Y. Zhou, K.E. Codispoti, and M.A. Kraut In vivo fibrillar β-amyloid detected by [11C]PiB PET and neuropathology in older adults Arch Neurol 68 2011 232 240
12. M.A. Burack, J. Hartlein, H.P. Flores, L. Taylor-Reinwald, J.S. Perlmutter, and N.J. Cairns In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia Neurology 74 2010 77 84
13. 11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease Neurology 67 2006 446 452
14. H.J. Aizenstein, R.D. Nebes, J.A. Saxton, J.C. Price, C.A. Mathis, and N.D. Tsopelas Frequent amyloid deposition without significant cognitive impairment among the elderly Arch Neurol 65 2008 1509 1517
15. J.C. Morris, C.M. Roe, C. Xiong, A.M. Fagan, A.M. Goate, and D.M. Holtzman APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging Ann Neurol 67 2010 122 131
16. C.C. Rowe, K.A. Ellis, M. Rimajova, P. Bourgeat, K.E. Pike, and G. Jones Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 31 2010 1275 1283
17. N.M. Kemppainen, S. Aalto, I.A. Wilson, K. Nagren, S. Helin, and A. Bruck PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment Neurology 68 2007 1603 1606
18. K.E. Pike, G. Savage, V.L. Villemagne, S. Ng, S.A. Moss, and P. Maruff β-Amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease Brain 130 2007 2837 2844
19. A. Forsberg, H. Engler, O. Almkvist, G. Blomguist, G. Hagman, and A. Wall PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiol Aging 29 2008 1456 1465
20. C.R. Jack Jr., V.J. Lowe, M.L. Senjem, S.D. Weigand, B.J. Kemp, and M.M. Shiung 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Brain 131 2008 665 680
21. J. Koivunen, T. Pirttilä, N. Kemppainen, S. Aalto, S.K. Herukka, and A.M. Jauhianen PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment Dement Geriatr Cogn Disord 26 2008 378 383
22. A. Okello, J. Koivunen, P. Edison, H.A. Archer, F.E. Turkheimer, and K. Någren Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study Neurology 73 2009 754 760
23. D.A. Wolk, J.C. Price, J.A. Saxton, B.E. Snitz, J.A. James, and O.L. Lopez Amyloid imaging in mild cognitive impairment subtypes Ann Neurol 65 2009 557 568
24. J.C. Morris, M. Storandt, D.W. McKeel Jr., E.H. Rubin, J.L. Price, and E.A. Grant Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease Neurology 46 1996 707 719
25. D.A. Bennett, J.A. Schneider, Z. Arvanitakis, J.F. Kelly, N.T. Aggarwal, and R.C. Shah Neuropathology of older persons without cognitive impairment from two community-based studies Neurology 66 2006 1837 1844
26. NBAC Report Research involving human biological materials: Ethical issues and policy guidance. Available at: http://hdl.handle.net/1805/22.
27. M.K. Cho Understanding incidental findings in the context of genetics and genomics J Law Med Ethics 36 2008 280 285
28. E.W. Clayton, and A.L. McGuire The legal risks of returning results of genomics research Genet Med 14 2012 473 477
29. P. Edison, H.A. Archer, R. Hinz, A. Hammers, N. Pavese, and Y.F. Tai Amyloid, hypometabolism, and cognition in Alzheimer disease: An[11C] PIB and [18F] FDG PET study Neurology 68 2007 501 508
30. S. Ng, V.L. Villemagne, S. Berlangieri, S.T. Lee, M. Cherk, and S.J. Gong Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease J Nucl Med 48 2007 547 552
31. P. Edison, H.A. Archer, A. Gerhard, R. Hinz, N. Pavese, and F.E. Turkheimer Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study Neurobiol Dis 32 2008 412 419
32. S.N. Gomperts, D.M. Rentz, E. Moran, J.A. Becker, J.J. Locascio, and W.E. Klunk Imaging amyloid deposition in Lewy body diseases Neurology 71 2008 903 910
33. C.M. Roe, M.A. Mintun, G. D'Angelo, C. Xiong, E.A. Grant, and J.C. Morris Alzheimer disease and cognitive reserve: Variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake Arch Neurol 65 2008 1467 1471
34. T. Hedden, K.R. van Dijk, J.A. Becker, A. Mehta, R.A. Sperling, and K.A. Johnson Disruption of functional connectivity in clinically normal older adults harboring amyloid burden J Neurosci 29 2009 12686 12694
35. W. Maetzler, I. Liepelt, M. Reimold, G. Reischl, C. Solbach, and C. Becker Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics Neurobiol Dis 34 2009 107 112
36. E.C. Mormino, J.T. Kluth, C.M. Madison, G.D. Rabinovici, S.L. Baker, and B.L. Miller Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects Brain 132 2009 1310 1323
37. R.A. Sperling, P.S. Laviolette, K. O'Keefe, J. O'Brien, D.M. Rentz, and M. Pihlajamaki Amyloid deposition is associated with impaired default network function in older persons without dementia Neuron 63 2009 178 188
38. P. Bourgeat, G. Chetelat, V.L. Villemagne, J. Fripp, P. Raniga, and K. Pike Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia Neurology 74 2010 121 127
39. D.P. Devanand, A. Mikhno, G.H. Pelton, K. Cuasay, G. Pradhaban, and J.S. Kumar Pittsburgh Compound B (11C-PIB) and Fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls J Geriatr Psychiatry Neurol 23 2010 185 198
40. E.C. Mormino, A. Smiljic, A.O. Hayenga, Onami SH, M.D. Greicius, and G.D. Rabinovici Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging Cereb Cortex 21 2011 2399 2407
41. H. Oh, E.C. Mormino, C. Madison, A. Hayenga, A. Smiljic, and W.J. Jagust Beta-amyloid affects frontal and posterior brain networks in normal aging Neuroimage 54 2011 1887 1895
42. K.A. Johnson, M. Gregas, J.A. Becker, C. Kinnecom, D.H. Salat, and E.K. Moran Imaging of amyloid burden and distribution in cerebral amyloid angiopathy Ann Neurol 62 2007 229 234
43. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration Neurology 68 2007 1205 1212
44. H. Engler, A.F. Santillo, S.X. Wang, M. Lindau, I. Savitcheva, and A. Nordberg In vivo amyloid imaging with PET in frontotemporal dementia Eur J Nucl Med Mol Imaging 35 2008 100 106
45. T. Suotunen, J. Hirvonen, P. Immonen-Raiha, S. Aalto, I. Lisinen, and E. Arponen Visual assessment of [(11)C]PIB PET in patients with cognitive impairment Eur J Nucl Med Mol Imaging 37 2010 1141 1147
46. N. Tolboom, W.M. van der Flier, J. Boverhoff, M. Yaqub, M.P. Wattjes, and P.G. Raijmakers Molecular imaging in the diagnosis of Alzheimer's disease: Visual assessment of [11C]PIB and [18F]FDDNP PET images J Neurol Neurosurg Psychiatry 81 2010 882 884
47. J.C. Morris, C.M. Roe, E.A. Grant, D. Head, M. Storandt, and A.M. Goate Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease Arch Neurol 66 2009 1469 1475
48. M. Storandt, M.A. Mintun, D. Head, and J.C. Morris Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: Cognitive decline associated with Abeta deposition Arch Neurol 66 2009 1476 1481
49. S.M. Resnick, J. Sojkova, Y. Zhou, Y. An, W. Ye, and D.P. Holt Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB Neurology 74 2010 807 815
50. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 263 269
51. Burgess S FDA approves imaging drug Amyvid; 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm299678.htm. Accessed on July 27, 2012.
52. S. Larrieu, L. Letenneur, J.M. Orgogozo, C. Fabrigoule, H. Amieva, and N. Le Carret Incidence and outcome of mild cognitive impairment in a population-based prospective cohort Neurology 59 2002 1594 1599
53. M. Ganguli, H.H. Dodge, C. Shen, and S.T. DeKosky Mild cognitive impairment, amnestic type: An epidemiologic study Neurology 63 2004 115 121
54. K. Palmer, L. Backman, B. Winblad, and L. Fratiglioni Mild cognitive impairment in the general population: Occurrence and progression to Alzheimer disease Am J Geriatr Psychiatry 16 2008 603 611
55. A.J. Mitchell, and M. Shiri-Feshki Rate of progression of mild cognitive impairment to dementia - meta analysis of 41 robust inception cohort studies Acta Psychiatr Scand 119 2009 252 265
56. M. Ganguli, B.E. Snitz, J.A. Saxton, C.C. Chang, C.W. Lee, and J. Vander Bilt Outcomes of mild cognitive impairment by definition: A population study Arch Neurol 68 2011 761 767
57. G.A. Jicha, J.E. Parisi, D.W. Dickson, K. Johnson, R. Cha, and R.J. Ivnik Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia Arch Neurol 63 2006 674 681
58. R.C. Petersen, J.E. Parisi, D.W. Dickson, K.A. Johnson, D.S. Knopman, and B.F. Boeve Neuropathologic features of amnestic mild cognitive impairment Arch Neurol 63 2006 665 672
59. W.J. Jagust, D. Bandy, K. Chen, N.L. Foster, A. Landau, and C.A. Mathis The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core Alzheimers Dement 6 2010 221 229
60. J. Koivunen, N. Scheinin, J.R. Virta, S. Aalto, T. Vahlberg, and K. Nagren Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study Neurology 76 2011 1085 1090
61. V.L. Villemagne, K.E. Pike, G. Chetelat, K.A. Ellis, R.S. Mulligan, and P. Bourgeat Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease Ann Neurol 69 2011 181 192
62. L.E. Hebert, J.L. Bienias, N.T. Aggarwal, R.S. Wilson, D.A. Bennett, and R.C. Shaw Change in risk of Alzheimer disease over time Neurology 75 2010 786 791
63. C.V. Fernandez, E. Kodish, and C. Weijer Informing study participants of research results: An ethical imperative IRB 25 2003 12 19
64. H.S. Richardson Incidental findings and ancillary-care obligations J Law Med Ethics 36 2008 256 270
65. P.A. Schulte Ethical issues in the communication of results J Clin Epidemiol 44 Suppl 1 1991 57S 61
66. R., Kollek, and I. Petersen Disclosure of individual research results in clinico-genomic trials: Challenges, classification and criteria for decision-making J Med Ethics 37 2011 271 275
67. D., Wendler, and E.J. Emanuel The debate over research on stored biological samples: What do sources think? Arch Intern Med 162 2002 1457 1462
68. J.S. Goldman, S.E. Hahn, J.W. Cantania, S. LaRusse-Eckert, M.B. Butson, and M. Rumbaugh Genetic counseling and testing for Alzheimer's disease: Joint practice guidelines of the American College of medical Genetics and the National Society of Genetic Counselors Genet Med 13 2011 597 605
69. International Huntington Association and World Federation on Neurology Research Group on Huntington's Chorea Guidelines for the molecular genetics predictive test in Huntington's disease J Med Genet 31 1994 555 559
70. Analysis and proposed actions regarding the National Bioethics Advisory Commission (NBAC) report. Research involving human biological materials: Ethical issues and policy guidance. Available at: http://aspe.hhs.gov/sp/hbm/report.htm /.
71. Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 110 Stat. 2029. Available at: http://library.clerk.house.gov/reference/ . Accessed on July 27, 2012.